Madrigal's Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts

May 6, 2026 11:17 AM EDT News Briefing Madri­gal MASH drug beats ex­pec­ta­tions; Gilead cuts jobs; in­vest­ment firm de­buts ENDPOINTS 🚀 Madri­gal Phar­ma­ceu­ti­cals’ MASH drug beats ex­pec­ta­tions: The biotech’s Rezd­if­fra sales came in at $311 mil­lion for the first quar­ter, sur­pass­ing an­a­lysts’ pro­jec­tions by about … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER